None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients undergoing pulsed field ablation (PFA) for atrial fibrillation (AF) for the first time. 2. Patients with documented failure of at least one antiarrhythmic drug therapy or with a medical contraindication to the use of antiarrhythmic drugs. 3. Patients who are able to voluntarily provide written informed consent after receiving a full explanation of the study. 4. Patients aged 18 years or older. 5. Patients with sufficient mental and linguistic capacity to understand the purpose of the clinical trial and to comply appropriately with the study procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of prior catheter ablation for atrial fibrillation. 2. Patients with comorbid conditions expected to limit life expectancy to less than one year. 3. Patients who have participated in, or are currently participating in, a clinical trial involving drugs, medical devices, or biologics within the past 2 months. 4. Pregnant or breastfeeding women, or women of childbearing potential who are not using adequate contraception. 5. Patients with a history of hemorrhagic disorders or cerebrovascular accidents within the past 3 months, or with ongoing such conditions. 6. Patients with active systemic infections or inflammatory diseases. 7. Patients who have undergone cardiac surgery or percutaneous coronary intervention (PCI) within 3 months prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Freedom from atrial tachyarrhythmia recurrence;Incidence of procedure-related adverse events or complications | — |
Secondary
| Measure | Time frame |
|---|---|
| Total procedure duration | — |
Countries
Korea, Republic of
Contacts
Chung-Ang University Gwangmyeong Hospital